Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:activities |
bradykinin B1 receptor antagonist
|
| gptkbp:clinical_trial |
Phase 3
|
| gptkbp:developed_by |
gptkb:Bio_Cryst_Pharmaceuticals
|
| gptkbp:effective_date |
December 2020
FDA approved |
| https://www.w3.org/2000/01/rdf-schema#label |
Berotralstat
|
| gptkbp:ingredients |
C18 H24 N2 O3 S
|
| gptkbp:is_used_for |
treatment of hereditary angioedema
|
| gptkbp:manager |
oral
|
| gptkbp:marketed_as |
Orladeyo
|
| gptkbp:side_effect |
headache
nausea abdominal pain diarrhea |
| gptkbp:targets |
bradykinin
|
| gptkbp:bfsParent |
gptkb:Bio_Cryst_Pharmaceuticals
|
| gptkbp:bfsLayer |
6
|